- Telehealth company eMed and Quest Diagnostics Inc DGX have collaborated for clinician-guided rapid antigen testing for COVID-19 in workplaces.
- Through the collaboration, the two companies will leverage the BinaxNOW COVID-19 Ag Card Home Test, a self-administered nasal swab antigen test that provides results in 15 minutes.
- An eMed Certified Guide will virtually supervise the testing process, confirm employee identity, oversee proper sample collection, and authenticate results during a telehealth visit.
- Individuals will receive their validated results via a digital health pass on their smart device, and employers will have access to a portal with consolidated employee test results.
- Price Action: DGX shares are up 0.16% at $148.81 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
